Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group.

@article{Zehender1990IncidenceAC,
  title={Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group.},
  author={Manfred Zehender and Thomas Meinertz and Stefan H. Hohnloser and Annette Geibel and Joachim Hartung and K. U. Seiler and Hanjorg Just},
  journal={Clinical physiology and biochemistry},
  year={1990},
  volume={8 Suppl 3},
  pages={90-100}
}
Efficacy and safety of ketanserin was studied prospectively in a randomized and double-blind trial involving 221 patients treated for hypertension and/or coronary artery disease. Since ketanserin has been suggested to cause QTc prolongation, we investigated the incidence and severity of this effect, as well as its influence on the incidence of malignant… CONTINUE READING